22nd week of 2011 patent applcation highlights part 32 |
Patent application number | Title | Published |
20110129438 | IMMUNOGENIC PROTEIN CONSTRUCTS - Bacterial immunity proteins are utilized to increase immune response to an antigen of interest. | 2011-06-02 |
20110129439 | CONDITIONED MEDIUM OF LIVER PROGENITOR CELLS - The invention is in the field of regenerative medicine. It has been found that the conditioned medium of non-oval pluripotent liver progenitor cells exerts a tissue regenerating effect. A preparation of the cell free conditioned medium is therefore useful in the treatment of injury and organ failure, preferably liver and/or injury or failure. | 2011-06-02 |
20110129440 | Heterocyclic Urea and Thiourea Derivatives and Methods of Use Thereof - The present invention relates to novel Heterocyclic Urea and Thiourea Derivatives of formula (I), compositions comprising the Heterocyclic Urea and Thiourea Derivatives, and methods for using the Heterocyclic Urea and Thiourea Derivatives for treating or preventing a proliferative disorder, an anti-proliferative disorder, inflammation, arthritis, a central nervous system disorder, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral infection, a fungal infection, or a disorder related to the activity of a protein kinase. | 2011-06-02 |
20110129441 | METHOD AND SYSTEM TO REMOVE SOLUBLE TNFR1, TNFR2, AND IL2 IN PATIENTS - A method, and system, to induce remission in diseases characterized by excess production of sTNR and interleukin 2 has been developed. In the most preferred embodiment, the system consists of antibodies to sTNFR1, sTNFR2 and sIL2R immobilized in a column containing a material such as SEPHAROSE™. The patient is connected to a pheresis machine which separates the blood into the plasma and red cells, and the plasma is circulated through the column until the desired reduction in levels of sTNFR1, sTNFR2, and IL2 is achieved, preferably to less than normal levels. In the preferred method, patients are treated three times a week for four weeks. This process can be repeated after a period of time. Clinical studies showed reduction in tumor burden in patients having failed conventional chemotherapy and radiation treatments. | 2011-06-02 |
20110129442 | LIPOIC ACID PELLET COMPOSITION - The present invention concerns a new composition based on pellets of lipoic acid in a lipophilic medium, if necessary combined with other active ingredients. | 2011-06-02 |
20110129443 | MACROCYCLIC SERINE PROTEASE INHIBITORS - Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula Ia or Ib, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof. | 2011-06-02 |
20110129444 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 2011-06-02 |
20110129445 | COMBINATIONS COMPRISING METHOTREXATE AND DHODH INHIBITORS - The present disclosure relates to combinations comprising (a) methotrexate, and (b) a DHODH inhibitor and their uses. | 2011-06-02 |
20110129446 | Clone of newcastle disease virus, its manufacture and its application in the medical treatment of cancer - A new clone of Newcastle disease virus which is interferon insensitive and has an ICPI between 1.2 and 2.0 and which may be used in the treatment of cancer and other diseases. | 2011-06-02 |
20110129447 | Methods for Cell Expansion and Uses of Cells and Conditioned Media Produced Thereby for Therapy - A method of cell expansion is provided. The method comprising culturing adherent cells from placenta or adipose tissue under three-dimensional culturing conditions, which support cell expansion. | 2011-06-02 |
20110129448 | METHODS TO MOBILIZE PROGENITOR/STEM CELLS - Methods to elevate progenitor and stem cell counts in animal subjects using compounds which bind to the chemokine receptor CXCR4 are disclosed. Preferred embodiments of such compounds are of the formula | 2011-06-02 |
20110129449 | COMPENSATING FOR ATRIOVENTRICULAR BLOCK USING A NUCLEIC ACID ENCODING A SODIUM CHANNEL OR GAP JUNCTION PROTEIN - A method of increasing the velocity of AV conduction in a mammal that may be in heart block or at risk of heart block by causing, in an AV node and/or His bundle having less than normal conduction speed, the expression of a sodium channel or gap junction protein, such as the SkM-1 channel, Cx43 or Cx32, so as to increase the velocity of conduction by the AV node. | 2011-06-02 |
20110129450 | METHOD OF PROMOTING NEUROGENESIS BY MODULATING SECRETASE ACTIVITIES - This invention provides methods and reagents for promoting neurogenesis, by modulating neural stem cell proliferation and differentiation. Particularly, this invention provides methods and reagents for promoting neurogenesis in a patient's central nervous system where the patient suffers from an aging-related neurodegenerative disease. Specifically, the invention provides methods for promoting neurogenesis comprising modulating the α and/or γ-secretase activities. | 2011-06-02 |
20110129451 | METHOD FOR DECREASING BORBORYGMI BY ADMINISTERING A BIFIDOBACTERIUM BACTERIA - The present invention relates to a method for decreasing borboiygmi in a subject by administering a probiotic, preferably a bacteria of the | 2011-06-02 |
20110129452 | PROBIOTICS TO INCREASE IgA SECRETION IN INFANTS BORN BY CAESAREAN SECTION - Use of probiotic bacteria in the manufacture of a medicament or therapeutic nutritional composition for increasing IgA secretion in an infant delivered by cesarean section during the first four months of the life of the infant. | 2011-06-02 |
20110129453 | Topical skin composition and method for moisturizing the skin - A cosmetic composition with superior moisturizing benefits comprising from approximately 0.3% to approximately 0.9% by weight of bio-chelated mineral blend comprising silicon, magnesium, copper, iron, zinc, and calcium, and at least approximately 85.0% by weight of a humectant blend. Preferably, the bio-chelated mineral blend comprise | 2011-06-02 |
20110129454 | COMPOSITIONS AND METHODS COMPRISING SERRATIA PEPTIDASE FOR INHIBITION AND TREATMENT OF BIOFILMS RELATED TO CERTAIN CONDITIONS - Physiologically acceptable anti-biofilm compositions comprising | 2011-06-02 |
20110129455 | INHIBITORS OF AKT ACTIVITY - Invented are novel pyrrole compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis. | 2011-06-02 |
20110129456 | Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer - The present invention relates to the sequential administration of a cytotoxic agent followed by an IGF1R antagonist (e.g., an antibody) for the treatment of hyperproliferative disorders including cancer. | 2011-06-02 |
20110129457 | VARIANT HHIP1 PROTEIN AND METHODS AND USES THEREOF - The present invention is directed to derivatives of Hhip1 and methods of using the same for treatment and diagnosis of cancer in mammals. | 2011-06-02 |
20110129458 | BINDING MOLECULES WITH MULTIPLE BINDING SITES, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF - The present invention relates to binding molecules, such as amino acid sequences with multiple antigen binding sites. In particular, the binding molecules of the present invention have at least two antigen binding sites that partially or fully overlap with each other and that are directed against at least two different naturally occurring binding molecules. The invention further relates to uses of such binders, for example in methods for inhibiting and/or blocking of the interaction between said at least two naturally occurring binding molecules and a third naturally occurring binding molecule. | 2011-06-02 |
20110129459 | ANTI-NR10 ANTIBODY AND USE THEREOF - The present inventors successfully obtained anti-NR10 antibodies having an effective neutralizing activity against NR10. The anti-NR10 antibodies provided by the present invention are useful as, for example, pharmaceuticals for treating or preventing inflammatory diseases. | 2011-06-02 |
20110129460 | Combination Antibodies For The Treatment And Prevention Of Disease Caused By Bacillus Anthracis And Related Bacteria And Their Toxins - The invention relates to methods and compositions for the prevention and treatment of disease caused by | 2011-06-02 |
20110129461 | Mat II Beta Subunit RNAi and Therapeutic Methods Using Same - The presently disclosed subject matter generally relates to methods and compositions for modulating MAT II activity. More particularly, the presently disclosed subject matter relates to methods and compositions for inhibiting the expression of MAT II β subunit in a subject via RNAi by administering siRNA or shRNA molecules directed to MAT II β subunit. In some embodiments, the methods and compositions of the presently disclosed subject matter generally relates to the treatment of cancer. More particularly, the methods and compositions of the presently disclosed subject matter relates to the inhibition of MAT II β subunit for the treatment of leukemia. | 2011-06-02 |
20110129462 | INTRANASAL ADMINISTRATION OF ACTIVE AGENTS TO THE CENTRAL NERVOUS SYSTEM - Pharmaceutical compositions and methods for delivering a polypeptide to the central nervous system of a mammal via intranasal administration are provided. The polypeptide can be a catalytically active protein or an antibody, antibody fragment or antibody fragment fusion protein. The polypeptides are formulated with one or more specific agents. | 2011-06-02 |
20110129463 | Quinazolin-4(3A)-One Derivatives and Methods of Use Thereof - Provided are quinazolin-4(3A)-one derivatives, which are inhibitors of the ubiquitin ligase activity of a human polypeptide, particularly to POSH inhibitors, and to compositions and methods for the treatment RING E3 ubiquitin ligase related diseases. | 2011-06-02 |
20110129464 | HUMANIZED ANTI-ERBB2 ANTIBODIES AND TREATMENT WITH ANTI-ERBB2 ANTIBODIES - The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies. | 2011-06-02 |
20110129465 | Mammalian Receptor Proteins; Related Reagents and Methods - Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described. | 2011-06-02 |
20110129466 | METHODS OF TREATING CANCER BY ADMINISTERING ANTIBODIES TO CD200 - Methods and compositions for regulating immunity are disclosed. For enhancing an immune response, agents that inhibit OX-2 are administered. Such methods are useful in treating cancer. For suppressing an immune response, an OX-2 protein or a nucleic acid encoding an OX-2 protein is administered. Such methods are useful in preventing graft rejection, fetal loss, autoimmune disease, allergies and in inducing tumor cell growth. | 2011-06-02 |
20110129467 | THERAPEUTIC COMBINATION COMPRISING AN AURORA KINASE INHIBITOR AND ANTIPROLIFERATIVE AGENTS - The present invention provides a combination comprising a compound 1 of formula (A) and one or more antineo-plastic agents selected from the group consisting of an antibody inhibiting a growth factor or a receptor of the growth factor, a proteasome inhibitor or a derivative or prodrug thereof, and a kinase inhibitor or a derivative or prodrug thereof useful in the treatment of tumors. | 2011-06-02 |
20110129468 | PURIFIED IMMUNOGLOBULIN FUSION PROTEINS AND METHODS OF THEIR PURIFICATION - The invention provides methods and compositions for separating impurities during the manufacture of immunoglobulin (Ig) fusion proteins. Examples of impurities which may be removed in accordance with the methods of the invention include inactive forms of the Ig fusion protein and/or aggregates. | 2011-06-02 |
20110129469 | METHODS FOR TREATING FATTY LIVER DISEASE - In certain aspects, the present invention provides compositions and methods for treating fatty liver disease by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies and anti-activin A or B antibodies. A variety of hepatic and metabolic disorders may be improved by treating fatty liver disease. | 2011-06-02 |
20110129470 | USE OF SPECIFICALLY ENGINEERED ENZYMES TO ENHANCE THE EFFICACY OF PRODRUGS - The invention provides methods for enhancing efficiency of prodrugs by specifically engineered enzymes with altered or enhanced activity and broader substrate specificity towards nucleoside analogs used in cancer chemotherapy, and delivering the enzymes to specific target cells in a patient. The invention also provides modified deoxycytidine kinase (dCK) mutants with such enhanced activities. Furthermore, the invention provides antibody-conjugated enzymes, pharmaceutical composition and kit containing the same, that can be specifically delivered to tumor cells. | 2011-06-02 |
20110129471 | Chronic lymphocytic leukemia cell line - The preparation and characterization of antibodies that bind to antigens on CLL or other cancer cells, especially to antigens upregulated in the cancer cells, and the identification and characterization of antigens present on or upregulated by cancer cells are useful in studying and treating cancer. | 2011-06-02 |
20110129472 | METHODS FOR CONTROLLING VASCULOGENESIS - The present invention relates to a method for detecting the presence and/or progress of vasculogenesis in a subject, said method comprising the steps of detecting the presence of activated endothelial progenitor cells (EPCs) in a sample of a circulation fluid of said subject. | 2011-06-02 |
20110129473 | VHNAR ANTI-CYTOKINE DOMAINS - The present invention concerns therapeutic compositions containing proteins that are the variable regions of IgNAR immunoglobulins, denominated vNAR, that specifically bind and neutralizes cytokines involved in a diversity of process such as inflammation and neovascularization, its ability to reach, bind, and neutralize the activity of one antigenic molecule localized in an immunoprivileged organs, are also described. | 2011-06-02 |
20110129474 | Methods And Systems For Multi-Antibody Therapies - The present invention relates to methods and systems for administering antibody therapeutic agents. The methods include administering one or more (e.g., two or three) binding agents, wherein each of the binding agents has one or more monomers that have a binding region that is specific to a portion of a disease agent and one or more copies of a tag. The binding agents can be specific to one or more portions of the same or different disease agents. The tag is the same for each of the binding agents. The methods include administering an anti-tag antibody, wherein the anti-tag antibody has an anti-tag region that is specific to the tag, and can have an immunoglobulin (e.g., IgA, IgD, IgE, IgG, and IgM.). Disease agents include bacteria, bacterial proteins, viruses, viral proteins, cancer cells, and proteins or toxins produced therefrom or from other sources such as snakes, insects, plants, etc. In particular, the present invention includes methods and systems for binding agents having one or more monomers that are specific to neurotoxins that cause botulism. | 2011-06-02 |
20110129475 | BASB 205 POLYPEPTIDES AND POLYNUCLEOTIDES FROM HAEMOPHILUS INFLUENZAE - The invention provides BASB205 polypeptides and polynucleotides encoding BASB205 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses. | 2011-06-02 |
20110129476 | MZB1, A NOVEL B CELL FACTOR, AND USES THEREOF - The marginal zone (MZ) and B1 subsets of B cells, which differ from conventional follicular (FO) B cells both developmentally and functionally, are involved in early responses to infectious pathogens and the production of self-reactive antibodies. A novel gene, mzb1, is expressed at high levels in MZ and B1 B cells but at low level, if at all, in FOB cells. MZB1 is involved in the regulation of proliferation, BCR-mediated signal transduction, and antibody production in B cells. Inhibitors, activators and enhancers of MZB1 expression or activity can be used as immune modulators for research and therapeutic purposes. | 2011-06-02 |
20110129477 | NOGO Receptor Homologs - The invention relates generally to genes that encode proteins that inhibit axonal growth. The invention relates specifically to genes encoding NgR protein homologs in humans and mice. The invention also includes compositions and methods for modulating the expression and activity of Nogo and the NgR proteins. Specifically, the invention includes peptides, proteins and antibodies that block Nogo-mediated inhibition of axonal extension. The compositions and methods of the invention are useful in the treatment of cranial or cerebral trauma, spinal cord injury, stroke or a demyelinating disease. | 2011-06-02 |
20110129478 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF CANCER - An antibody or a fragment thereof having immunoreactivity to a polypeptide comprising not less than 7 continuous amino acids in the CD179b protein, which was identified as a cancer antigen protein specifically expressed on the surfaces of cancer cells, can be used as a pharmaceutical composition for therapy and/or prophylaxis of cancer. | 2011-06-02 |
20110129479 | IMMUNOGEN SELECTION DIRECTED IN IMMUNOGLOBULIN PACKAGES IN PLASMA AND COLOSTRUM AND METHOD OF MAKING AND USING SAME - A method for the selection and production of group specific immunoglobulins to bind to specific microbes or their toxins is provided. The immunoglobulins are produced in animals and collected either in the plasma or colostrums of the animals after being challenged with a series of selected immunogens. The selected immunoglobulins are packaged into products against specific groups of microbes or their toxins. These packages are delivered to animals including humans. These products could be used as passive protectants. The packages could be developed into products to protect animals or humans against diseases until vaccines can be effectively administered. | 2011-06-02 |
20110129480 | ANTI-FERROPORTIN 1 MONOCLONAL ANTIBODIES AND USES THEREOF - Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of human FPN1, and which are effective in maintaining or increasing the transport of iron out of mammalian cells and/or maintaining or increasing the level of serum iron, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a subject in vivo. | 2011-06-02 |
20110129481 | Antibody specifically binding to c-Met and methods of use - Antibodies specifically binding to c-Met protein, hybridoma cell lines, and compositions comprising the antibodies are disclosed herein. Methods of making and using the antibodies and compositions are also disclosed. | 2011-06-02 |
20110129482 | POLYPEPTIDE COMPOUNDS FOR INHIBITING ANGIOGENESIS AND TUMOR GROWTH - In certain embodiments, this present invention provides polypeptide compositions, and methods for inhibiting Ephrin B2 or EphB4 activity. In other embodiments, the present invention provides methods and compositions for treating cancer or for treating angiogenesis-associated diseases. | 2011-06-02 |
20110129483 | Membrane transporter NaPi2b (SCL34A1) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy - The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide (s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided. | 2011-06-02 |
20110129484 | IMMUNOTHERAPIES EMPLOYING SELF-ASSEMBLING VACCINES - Provided herein are self-assembling pharmaceutical compositions comprising a heat shock protein fused to a biotin-binding protein, wherein the biotin-binding protein is non-covalently bound to four biotinylated components, and further wherein at least two of the four biotinylated components are not identical. | 2011-06-02 |
20110129485 | Modified Galectin-2 and Uses Thereof - An isolated modified galectin-2 protein comprising a mutation and/or modification which improves one or more properties of said isolated modified galectin-2 are provided. More particularly, the mutation of galectin-2 is substitution of cysteine 57, preferably with a methionine residue. Modification of an isolated galectin-2 includes a modification of cysteine 75. Modification includes chemical modification by PEGylation or alkylation. Also provided are isolated nucleic acid, genetic constructs comprising said isolated nucleic acids, antibodies, compositions and methods of modulating an immune response that may be useful in therapeutic and/or prophylactic treatment of disease, disorders or considers which involve an immune response is mediated by one or more cytokines or other soluble immunomodulators and/or the immune response is mediated by one or more cells of the immune system. | 2011-06-02 |
20110129486 | METHODS OF TREATING INFLAMMATORY COLON DISEASES - A method of treating ulcerative colitis or Crohn's disease in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of adherent cells from a placenta or adipose tissue, thereby treating the ulcerative colitis or Crohn's disease. | 2011-06-02 |
20110129487 | PLASMIC PRODUCTION AND EXPRESSION OF RECOMBINANT PROTEINS IN CELLS GROWN WITHOUT ANTIBIOTICS - The invention relates to a mutated cell such as a bacteria or yeast in which the thyA gene coding thymidylate synthase includes a nonsense codon, preferably the amber codon, said nonsense codon replacing a codon coding an amino acid and inducing the interruption of thyA gene translation and the auxotrophy of the cell for the thymidine. Advantageously, the endA gene coding the endonuclease 1 and/or the recA gene coding the recombinase is inactivated in said mutated cell. The invention also relates to an expression plasmid including a transgene and a sequence of a suppressing ARM structural gene containing an anticodon that can be paired with the nonsense codon of the thyA gene and is specific of an amino acid capable of restoring the translation of the mutated thyA gene and thereby obtaining a protein of the wild or mutated type having a thymidylate synthase activity. The invention also relates to a method for the multiplication of the expression plasmid. | 2011-06-02 |
20110129488 | IMMUNOTHERAPY COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF AMYLOIDOSIS - The invention relates to immunogenic peptide sequences and antibodies against said immunogenic agents for treating, preventing and/or diagnosing in human and non-human mammals a disease which is characterized by amyloid deposition, including involutive depression, confusional syndrome, dysthymia and cognitive Dysfunction Syndrome (CDS) in non-human mammals and different amyloidosis, including Alzheimer's disease in humans. Moreover, the invention provides diagnostic methods for the above diseases using the antibodies of the invention. | 2011-06-02 |
20110129489 | METHODS FOR GENERATING AN IMMUNE RESPONSE USING DNA AND A VIRAL VECTOR - The present invention relates to the generation of an immune response against a target antigen using a DNA and viral vector in a specific administration pattern. | 2011-06-02 |
20110129490 | MODULATION OF PRODUCTION OF RETROVIRUSES BY APOBEC4 - The invention relates to APOBEC4 proteins and N- or C-terminally modified APOBEC4 proteins for the modulation of the release of retroviruses or viral particles thereof from cells and various uses thereof. Expression of APOBEC4 or N-terminally stabilized APOBEC4 protein in a cell leads to an increased viral production, while expression of C-terminally modified APOBEC4 protein leads to a decrease in viral production. | 2011-06-02 |
20110129491 | Anti-Inflammatory Hydrolysate of C. versicolor - Methods and compositions for reducing and/or inhibiting inflammation by topical application of dermatocosmetic compositions comprising effective amounts of extracts of | 2011-06-02 |
20110129492 | Immunostimulatory Recombinant Intracellular Pathogen Immunogenic Compositions and Methods of Use - Immunogenic compositions comprising recombinant intracellular pathogens that have been transformed to express recombinant immunogenic antigens of the same or other intracellular pathogens and immunostimulatory molecules are provided. Exemplary immunogenic compositions include, but are not limited to, recombinant BCG expressing | 2011-06-02 |
20110129493 | COMBINED MEASLES-HUMAN PAPILLOMA VACINE - The present invention relates to combined vaccines against measles and human papilloma virus (HPV). In particular, the invention relates to recombinant measles virus vectors containing heterologous nucleic acid encoding single or several antigens derived from HPV, preferably, the major capside antigen L1, the minor capside antigen L2, the early gene E6 and the early gene E7 oncoproteins of HPV type 16, and optionally of types 18, 6 and 11. In a first embodiment, prophylactic vaccines are generated expressing HPV antigens, preferably L1 and/or L2 such that they induce a potent long-lasting immune response in mammals, preferably humans, to protect against HPV and MV infection. In another embodiment, therapeutic vaccines are generated expressing E6 and E7 proteins, and optionally L1 and L2, such that they induced strong immune responses will resolve persistent HPV infections at early or late stages, including HPV-induced cervical carcinoma. In a preferred embodiment, the combined vaccines are easy to produce on a large scale and can be distributed at low cost. | 2011-06-02 |
20110129494 | Vaccine Formulations Comprising Saponin-containing Adjuvants - The present invention provides for a novel oil-in-water (O/W) emulsion, with increased stability in the presence of bacterial or viral suspensions, especially those concentrated and non-purified (crude extracts) or minimally purified. The emulsion of the present invention can act as vehicle for the delivery of a pharmaceutical composition comprising at least one immunogen and, in particular, an immunogen selected from the group consisting of an inactivated pathogen, an attenuated pathogen, a subunit, a recombinant expression vector, and a plasmid or combinations thereof. | 2011-06-02 |
20110129495 | TREATMENT OF PRDC IN PIGS - The present invention relates to the use of an immunogenic composition comprising a porcine circovirus type 2 (PCV2) antigen for the prevention and treatment, including a reduction in the severity of, duration of, and manifestations of, porcine respiratory disease complex (PRDC) in animals, preferably in pigs. | 2011-06-02 |
20110129496 | Use of mTOR Inhibitors to Enhance T Cell Immune Responses - It is disclosed herein that treatment of a subject with an mTOR inhibitor enhances antigen-specific T cell immune responses. Thus, provided herein is a method of enhancing an antigen-specific T cell response in a subject by administering to the subject a therapeutically effective amount of an mTOR inhibitor. The antigen can be any antigen, such as an antigen from a pathogen or a vaccine, or a tumor antigen. In some embodiments, the method further comprises administering to the subject a vaccine, such as a virus vaccine or a cancer vaccine. The mTOR inhibitor can be administered either before or after vaccination to enhance the quantity and quality of the T cell immune response and immunological memory. In some examples, the mTOR inhibitor is rapamycin or a rapamycin analog. | 2011-06-02 |
20110129497 | Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes - The instant invention comprises a process of preparing a composition comprising directed sequence polymer (DSP) mixtures that act as epitopes and useful as vaccines, such DSP synthesized according to a set of rules regarding the identity and the frequency of occurrence of amino acids that substitute a base or native amino acid of a known epitope. The resulting composition is a mixture of related peptides for therapeutic use as a vaccine, preferably for infectious agents that are immune evasive. | 2011-06-02 |
20110129498 | VACCINE FOR THE PREVENTION AND THERAPY OF HCV INFECTIONS - The present invention relates to CD81-binding peptides of the hepatitis virus C(HCV) E2 glycoprotein, which are devoid of or mutated within the amino-terminal 27 amino acids of the mature E2 envelope glycoprotein, or variant thereof which retains the ability to bind to CD81. Furthermore, the present invention provides polypeptides comprising said CD81-binding peptide, polynucleotides encoding the CD81-binding peptide, and expression cassettes and vectors comprising the polynucleotide of the invention. Moreover, the present invention relates to compositions comprising the CD81-binding peptide, the polynucleotide encoding the CD81-binding peptide, the expression cassette, or the vector, and an adjuvant. Furthermore, the present invention provides a pharmaceutical composition comprising the CD81-binding peptide, the polynucleotide, the expression cassette, the vector, or the composition of the invention, and a pharmaceutically acceptable excipient, carrier, or diluent. Moreover, the present invention provides the CD81-binding peptide, the polynucleotide, the expression cassette, the vector, the composition, or the pharmaceutical composition of the invention for induction of an immune response, preferably a broad specificity immune response, against HCV in a mammal, and methods for inducing a therapeutic and/or prophylactic immune response against HCV in a mammal, preferably against HCV of various genotypes. | 2011-06-02 |
20110129499 | DUAL DELIVERY SYSTEM FOR HETEROLOGOUS ANTIGENS - Provided herein are recombinant | 2011-06-02 |
20110129500 | LAWSONIA INTRACELLULARIS BACTERIUM OF A NOVEL SEROTYPE, VACCINE BASED ON THAT BACTERIUM, ANTIBODIES SUITABLE FOR DIAGNOSING THE NOVEL LAWSONIA INTRACELLULARIS SEROTYPE AND HYBRIDOMAS FOR PRODUCING THE SAID ANTIBODIES - This invention pertains to | 2011-06-02 |
20110129501 | VACCINE COMPRISING RECOMBINANT CLPP PROTEIN OF STREPTOCOCCUS PNEUMONIAE - A method for immunizing a human or animal against pneumococcal infections, comprising by administering a vaccine comprising a purified recombinant caseinolytic protease P (ClpP) protein of | 2011-06-02 |
20110129502 | Immunogenic Constructs - The present invention relates to molecules, which can be used to induce a therapeutic or prophylactic immune response against MAP. In particular, the present invention relates to polypeptides comprising an alipC polypeptide sequence, a gsd polypeptide sequence, a p12 polypeptide sequence and an mpa polypeptide sequence, wherein said ahpC polypeptide comprises the sequence of SEQ ID NO: 2, a variant thereof having more than 70% amino acid sequence identity to SEQ ID NO: 2 across the full length of SEQ ID NO: 2, or a fragment of at least 8 amino acids of SEQ ID NO: 2 which comprises an epitope; said gsd polypeptide comprises the sequence of SEQ ID NO: 6, a variant thereof having more than 70% amino acid sequence identity to SEQ ID NO: 6 across the full length of SEQ ID NO: 6, or a fragment of at least 8 amino acids of SEQ ID NO: 6 which comprises an epitope; said pi 2 polypeptide comprises the sequence of SEQ ID NO: 10, a variant thereof having more than 70% amino acid sequence identity to SEQ ID NO: 10 across the full length of SEQ ID NO: 10, or a fragment of at least 8 amino acids of SEQ ID NO: 10 which comprises an epitope; and said mpa polypeptide comprises the sequence of SEQ ID NO: 14, a variant thereof having more than 70% amino acid sequence identity to SEQ ID NO: 14 across the full length of SEQ ID NO: 14, or a fragment of at least 8 amino acids of SEQ ID NO: 14 which comprises an epitope. Preferably such a variant maintains the ability to generate an immune response against the unmodified polypeptide. | 2011-06-02 |
20110129503 | Tumor vaccination in combination with hematopoietic cell transplantation for cancer therapy - In one aspect, the present invention provides a method for treating cancer comprising tumor cell vaccination in combination with hematopoietic and immune cell transplantation. In some embodiments, the method involves autologous tumor cell vaccination prior to autologous hematopoietic and immune cell transplantation. In another aspect, the present invention provides a method of purifying tumor cells from a subject in preparation for vaccination. | 2011-06-02 |
20110129504 | COMPOSITION FOR CONTROLLING LIPASE CATALYZED REACTIONS - The present invention relates to the field of lipolysis mediated by lipases. In particular the present invention relates to the modulation of lipase activity by regulation of the composition of the interface between a hydrophobic and a hydrophilic phase. More particularly the present invention relates to a the use of a formulation comprising at least one surfactant with an interfacial pressure that is sufficiently high to control the access of lipase substrates to the interface between a lipophilic phase and a hydrophilic phase to regulate lipolysis and to a composition comprising at least one oil and enriched with at least one surfactant wherein the surfactant is non-cleavable by at least one lipase, has a higher affinity to the interface between the hydrophilic and lipophilic phase than the at least one lipid and is present in a weight ratio to the at least one lipid of about 1:1000-100:1. | 2011-06-02 |
20110129505 | CELLULOSE DERIVATIVE AND HYDROGEL THEREOF - The invention is a cellulose derivative wherein some of the carboxyl groups of the cellulose derivative carboxymethylcellulose are replaced with —CO—NH—X—CO—Y—Z, and a hydrogel of the same. In the formula, X is a C1-10 divalent hydrocarbon group, Y is a divalent group derived from polyalkylene oxide having oxygen atoms at both ends, and Z is a C1-24 hydrocarbon group or —CO—R | 2011-06-02 |
20110129506 | Colouring using pearlescent pigments in the food and pharmaceutical sectors - The present invention relates to the use of titanium dioxide pigments and/or iron oxide pigments based on platy substrates for colouring food products and pharmaceutical products. | 2011-06-02 |
20110129507 | CONTROLLED RELEASE FORMULATIONS EXHIBITING AN ASCENDING RATE OF RELEASE - A sustained release dosage form is comprising a pharmaceutically active agent and pharmaceutically acceptable salts thereof and adapted to release as an erodible solid over a prolonged period of time, wherein the dosage form provides an ascending rate of release of the pharmaceutically active agent for at least about 4 hours. The dosage form is able to deliver high doses of poorly soluble or slowly dissolving active agents. When additional pharmaceutically active agents are present, the agents are released from the dosage form at rates that are proportional to the respective weights of each active agent in the dosage form. Methods of using the dosage forms to treat disease or conditions in human patients are also disclosed. | 2011-06-02 |
20110129508 | METHODS AND COMPOSITIONS FOR THE MANAGEMENT OF PAIN USING OMEGA-CONOTOXINS - The present invention relates to the management of pain (nociceptive, neuropathic, inflammatory and disease related pains), using omega-conotoxins alone or in combination with neuronal excitation inhibitors (analgesics). The invention in particular provides methods, protocols, compositions and devices which treat, alleviate, prevent, diminish or otherwise ameliorate the sensation of pain. | 2011-06-02 |
20110129509 | Titanium Dioxide Dispersion And Cosmetics Containing The Same - The present invention provides a titanium dioxide dispersion having a good dispersibility and also provides a cosmetic containing the same. The titanium dioxide dispersion comprises (a) a hydrophobized, treated titanium dioxide powder; (b) one or more oils selected from isohexadecane, isododecane, 2-ethylhexyl 2-ethylhexanoate, isononyl isononate, 2-ethylhexyl isononanoate, isononyl 2-ethylhexanoate, and polypropylene glycol dipivalate; and (c) a siloxane compound represented by the following formula (1), preferably polyoxyalkylene/alkyl comodified organopolysiloxane. | 2011-06-02 |
20110129510 | FIBROUS SURFACE STRUCTURE CONTAINING ACTIVE INGREDIENTS WITH CONTROLLED RELEASE OF ACTIVE INGREDIENTS, USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF - The invention relates to a fibrous surface structure containing active ingredients with an adjustable active ingredient release profile, comprising a fibrous, polymeric, soluble and/or degradable active ingredient substrate and at least one active ingredient that is associated with the substrate and can be released by the fibrous surface structure; to formulations containing active ingredients, comprising such fibrous surface structures; to the use of fibrous surface structures containing active ingredients according to the invention for producing formulations containing active ingredients; and to a method for producing fibrous surface structures according to the invention. | 2011-06-02 |
20110129511 | PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME FOR REGULATION OF ANGIOGENESIS - Isolated polynucleotide sequences exhibiting endothelial cell specific promoter activity, novel cis regulatory elements and methods of use thereof enabling treatment of diseases characterized by aberrant neovascularization or cell growth are disclosed. | 2011-06-02 |
20110129512 | Antimicrobial Releasing Polymers - The present disclosure is directed to polymers having hydroxyl containing bioactive agents incorporated into the backbone of the polymer or attached thereto by pendant linkages. Hydroxyl containing bioactive agents which may be attached to these polymers include antimicrobial agents such as triclosan. The polymers may be utilized to form medical devices or coatings for such devices. The hydroxyl containing bioactive agent may be released from the polymer upon hydrolysis of the polymeric backbone or pendant linkage in vivo. | 2011-06-02 |
20110129513 | COMPOSITIONS AND METHODS FOR COATING MEDICAL IMPLANTS - Medical implants are provided which release an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, and/or platinum complex, thereby inhibiting or reducing the incidence of infection associated with the implant. | 2011-06-02 |
20110129514 | Hygroscopic coating on a balloon device - The present invention provides a hygroscopic coating on a balloon for an implantable device and methods of making and using the same. | 2011-06-02 |
20110129515 | Devices and Methods for Nerve Regeneration - The present invention is directed to a nerve regeneration conduit including a resorbable tube having a matrix therein. The matrix is characterized by substantially parallel, axially aligned pores extending the length of the matrix. The matrix is formed by the axial freezing of a slurry having little or no significant radial thermal gradient during the freezing process. The matrix is used to bridge the gap between the severed ends of a nerve and provide a scaffold for nerve regeneration. | 2011-06-02 |
20110129516 | OCULAR DRUG DELIVERY DEVICES - A method of forming an ocular delivery device includes exposing a solid, shaped cellulose polymer to a solution including an active pharmaceutical ingredient (API) and a solvent capable of solubilizing the API, wherein the polymer absorbs at least a portion of the solution, including the API and solvent. The method may further include removing at least a portion of the absorbed solvent from the polymer by allowing the absorbed solvent to evaporate from the polymer or by drying the polymer. A variety of cellulose polymers may be used, including hydroxypropyl cellulose. A variety of APIs may be used, including Cyclosporine, Tobramycin and Vancomycin. Ocular delivery devices prepared by the methods may be used to treat a variety of eye disorders. | 2011-06-02 |
20110129517 | TABLETTABLE CHEWING GUMS - The invention relates to certain nicotine chewing gums that provide for a high rate of buccal absorption and high plasma concentrations, in particular over the first 10 minutes after administration, in a subject willing to quit smoking. | 2011-06-02 |
20110129518 | Probiotic products for pet applications - An exemplary embodiment providing one or more improvements includes feeding animals with probiotic microbes encapsulated in a mixture of xanthan gum and chitosan, or in gelatin, specifically | 2011-06-02 |
20110129519 | Modafinil-Based Treatment For Premature Ejaculation - Methods and compositions comprising modafinil are described for treating premature ejaculation in a male individual. | 2011-06-02 |
20110129520 | Anti-Adhesion Barrier Wound Dressing Comprising Processed Amniotic Tissue and Method of Use - An anti-adhesion wound barrier fabricated from amnion obtained from human birth tissue and treated with a glutaraldehyde solution is provided. The amnion is treated in 1% glutaraldehyde solution for up to 15 minutes to fix the amnion. Methods of processing the birth tissue to prepare the amnion for use as a wound barrier are also provided. Use of the amnion anti-adhesion wound barrier for dressing wounds is also described. | 2011-06-02 |
20110129521 | PHARMACEUTICAL COMPOSITION CONTAINING A HYPOMETHYLATING AGENT AND A HISTONE DEACETYLASE INHIBITOR - A pharmaceutical composition for induction therapy which has a hypomethylating agent and a histone deacetylase inhibitor (“HDAC inhibitor”); wherein the hypomethylating agent is a DNA and histone methylation inhibitor such as cladribine and the HDAC inhibitor is, for example, entinostat, panobinostat, vorinostat, and/or romedepsin; further wherein the hypomethylating agent and the HDAC inhibitor are combined in formulations for various administrations including e.g., a continuous delivery system such as a transdermal patch of at least one reservoir or a plurality of reservoirs, oral, a fixed-dose oral combination, intravenous, and combinations thereof. This pharmaceutical composition for induction therapy is used with a monoclonal antibody in the treatment of various cancers, sarcomas, and other malignancies. | 2011-06-02 |
20110129522 | TRANSDERMAL SYSTEM FOR EXTENDED DELIVERY OF INCRETINS AND INCRETN MIMETIC PEPTIDES - A transdermal patch formulation of a viscous liquid that includes an active agent of incretin or incretin mimetic peptide, a stabilizer, a buffer, a water soluble thickening agent, and a pharmaceutically acceptable carrier. Also, a patch adapted for transdermal delivery of the active agent and having a drug reservoir compartment of the transdermal patch formulation and a system for facilitating transdermal delivery of the active agent through the skin of a subject. The system includes the patch and an apparatus capable of generating a plurality of micro-channels in an area on the subject's skin. The patch and apparatus are used in methods of treatment for reducing blood glucose level, lowering plasma glucagon levels, reducing food intake, or reducing gastric motility in a subject in need of the same by extending the release of the incretin or incretin mimetic peptide in the subject. | 2011-06-02 |
20110129523 | Liposomally Encapsulated Reduced Glutathione, including with Other Pharmacologic Preparation, Capable of Administration as an Oral, Topical, Intraoral or Transmucosal, Prepartion, for Reversal and Prevention of Oxidation of Cholesterol and of Low Density Lipoprotein - The invention proposes the sure of reduced glutathione in a liposome (liposomal reduced glutathione) for the oral administration of a therapeutically effective amount to ameliorate the progression of vascular disease, including atherosclerosis, diabetes, hypertension, narrowing of arteries leading to decreased blood flow, ischemic events, and the formation of blood clots, abnormal platelet aggregation, and thrombotic events, by reducing the amount and effect of oxidized cholesterol, oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with statin drugs to improve the effect of lowering not only cholesterol but also the oxidized cholesterol as well as oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with CoQ10 as a therapy for vascular disease and management of side effects of statin therapy. | 2011-06-02 |
20110129524 | THERAPEUTIC AGENT FOR CANCER, AND METHOD FOR TREATMENT OF CANCER - [Problems] To provide a technique which enables an effective antibody therapy for cancer which targets for FGFR1 without the need of using any effective antibody having high specificity and a potent cell-killing activity. | 2011-06-02 |
20110129525 | MUCOSAL MEMBRANE RECEPTOR AND USES THEREOF - The invention is based on the identification of aminopeptidase N (APN) as the receptor for F4 fimbriae of enterotoxigenic | 2011-06-02 |
20110129526 | COMPOSITIONS AND METHODS FOR TREATING VASCULAR DISEASE - The use of tPA to treat hemorrhagic transformation, neurotoxicity has been limited to short treatment time windows because a high dose of tPA required to generate sufficient amounts of the enzyme plasmin for clot lysis. The present invention combines tPA with recombinant Annexin A2 resulting in thrombolysis without hemorrhagic transformation at delayed times after stroke. This embodiment allows the administration of a lower, non-neurotoxic, tPA dose. Our results suggest this novel combination for stroke therapy may greatly improve both efficacy and safety, and prolong tPA therapeutic time window. | 2011-06-02 |
20110129527 | RAB3B FOR THE TREATMENT AND PREVENTION OF PARKINSON'S DISEASE - The invention features methods and compositions for the treatment and prevention of Parkinson's Disease. | 2011-06-02 |
20110129528 | SUSTAINED-RELEASE CHITOSAN CAPSULES COMPRISING CHITOSAN AND PHYTIC ACID - The present invention relates to a chitosan capsule in which a soluble active ingredient is encapsulated in a matrix containing chitosan and phytic acid; a cross-linking method and materials capable of being used in preparing the capsule; and pharmaceutical, food and cosmetic compositions comprising the capsule. The chitosan capsule according to the present invention is prepared via ionic gelation of chitosan as a biodegradable polymer with phytic acid capable of rapidly and effectively forming a cross-linking reaction with the chitosan polymer. The capsule of the present invention shows high encapsulation efficiency for a soluble active ingredient and protects the soluble active ingredient from being damaged in a digestive tract, resulting in improving an in vivo delivery efficiency of a physiologically active material. Further, since the capsule of the present invention has a pH-dependent sustained-release mechanism which can minimize the release of a soluble active ingredient in the stomach and gradually release in the intestine, it is possible to regulate sustained-release of a soluble active ingredient. | 2011-06-02 |
20110129529 | Probiotic products for pet applications - An exemplary embodiment providing one or more improvements includes feeding animals with probiotic microbes encapsulated in a mixture of xanthan gum and chitosan, or in gelatin, specifically | 2011-06-02 |
20110129530 | Compressible-Coated Pharmaceutical Compositions and Tablets and Methods of Manufacture - There is provided a method for preparing a pharmaceutical composition comprising compressible coated, taste-masked and/or controlled-release coated drug-containing particles, rapidly-dispersing microgranules comprising a disintegrant and a sugar alcohol, a saccharide, or a mixture thereof, and other optional, pharmaceutically acceptable excipients wherein the orally disintegrating tablet (ODT) or rapidly dispersing tablet (RDT) composition having acceptable tableting, organoleptic, and pharmacokinetic properties. | 2011-06-02 |
20110129531 | Dermal Fillers Comprising Silk Fibroin Hydrogels and Uses Thereof - The present specification provides compositions useful as dermal fillers and methods using such compositions to treat a condition of skin. | 2011-06-02 |
20110129532 | METHOD AND MEANS FOR TREATING VIRAL DISEASE, IN PARTICULAR HIV/AIDS - A method of treating viral disease, in particular HIV/AIDS, comprises concomitant administration of GnRH or GnRH analog including pharmaceutically acceptable salts thereof in an amount sufficient to maintain in the patient an elevated unphysiological plasma level, in particular a castrating plasma level, of GnRH or GnRH analog, and of one or several natural, semi-synthetic or synthetic sexual hormones in a amount sufficient to compensate for the castration effect of GnRH or GnRH analog. Also disclosed is a corresponding pharmaceutical composition and a composition kit, and uses thereof. | 2011-06-02 |
20110129533 | POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF - Drugs, especially low aqueous solubility drugs, are provided in a porous matrix form, preferably microparticles, which enhances dissolution of the drug in aqueous media. The drug matrices preferably are made using a process that includes (i) dissolving a drug, preferably a drug having low aqueous solubility, in a volatile solvent to form a drug solution, (ii) combining at least one pore forming agent with the drug solution to form an emulsion, suspension, or second solution and hydrophilic or hydrophobic excipients that stabilize the drug and inhibit crystallization, and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the porous matrix of drug. Hydrophobic or hydrophilic excipients may be selected to stabilize the drug in crystalline form by inhibiting crystal growth or to stabilize the drug in amorphous form by preventing crystallization. The pore forming agent can be either a volatile liquid that is immiscible with the drug solvent or a volatile solid compound, preferably a volatile salt. In a preferred embodiment, spray drying is used to remove the solvents and the pore forming agent. The resulting porous matrix has a faster rate of dissolution following administration to a patient, as compared to non-porous matrix forms of the drug. In a preferred embodiment, microparticles of the porous drug matrix are reconstituted with an aqueous medium and administered parenterally, or processed using standard techniques into tablets or capsules for oral administration. | 2011-06-02 |
20110129534 | REDUCTION OF DERMAL SCARRING - Methods and compositions for reducing or inhibiting dermal scarring by expressing p21 | 2011-06-02 |
20110129535 | TRANSDERMAL TESTOSTERONE DEVICE AND DELIVERY - Described are transdermal drug delivery systems for the transdermal administration of testosterone, comprising a polymer matrix and testosterone. Methods of making and using such systems also are described. | 2011-06-02 |
20110129536 | NANOCOMPOSITE MATERIALS BASED ON METALLIC NANOPARTICLES STABILIZED WITH BRANCHED POLYSACCHARIDES - The present invention provides nanocomposite systems made of metallic nanoparticles stabilized with branched cationic polysaccharides, in particular alditolic or aldonic mono- and oligo-saccharidic derivatives of chitosan, and their preparation obtainable with aqueous solutions of these polysaccharides in the presence or absence of reducing agents. The peculiar chemical and physical-chemical features of these polysaccharides allow to form metallic nanoparticles homogeneously dispersed in the polysaccharidic matrix and an effective stabilization thereof. The properties associated with the nanometric dimensions and the presence of biological signals on polymeric chains may be exploited in applications with antimicrobial activities and of molecular biosensors. | 2011-06-02 |
20110129537 | FUNCTIONALIZED METAL-COATED ENERGY CONVERTING NANOPARTICLES, METHODS FOR PRODUCTION THEREOF AND METHODS FOR USE - A functionalized nanoparticle, having a core, optionally having a shell on at least a portion thereof, wherein the core contains a material that can convert applied X-ray energy into emitted UV energy and wherein the shell, when present, contains a plasmonics active material; wherein the nanoparticle has on a surface thereof at least one psoralen compound capable of activation by the emitted UV energy, and the use of the functionalized nanoparticle in a method of treating a cell proliferation disorder such as cancer. | 2011-06-02 |